|Videos|August 7, 2020
Expedited Programs for Drug Approvals
Advertisement
Pharmaceutical Executive’s Lisa Henderson interviews Todd Phillips, PharmD, of Cardinal Health Regulatory Sciences about FDA’s expedited programs and key elements to consider before using this pathway.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026 Wrap Up: Pharma Leaders Speak About the Conference and the State of the Industry
2
Pharma Companies Raise List Prices, Including 16 That Had Agreements to Lower Prices with Trump Administration: Report
3
Henlius Enters Global Exclusive License Agreement with U-mab Biopharma for Best-in-Class Potential Anti-IL-1RAP mAb
4
Pharmaceutical Executive Daily: Henlius' Exclusive License Agreement with U-Mab Biopharma
5